https://www.selleckchem.com/products/vt107.html
Patients with NSCLC with leptomeningeal metastases (LM) presented dismal prognosis. Cerebrospinal fluid (CSF) is suggested as a medium of liquid biopsy of LM. However, the clinical implications of CSF genotyping on treatment outcomes remained elusive. Patients with EGFR-mutated advanced NSCLC with LM were included cohort 1, patients with LM who were treated with osimertinib with CSF and plasma genotyping performed before the first dosing of osimertinib (baseline, n= 45); cohort 2, CSF genotyping on progression on osimertinib and developme
Curtir
Comentario
Compartilhar
